Sarepta Therapeutics reported promise in initial findings from clinical studies of two RNA muscle disease treatments, as the company maps out a future beyond its

Beam Therapeutics has provided a much-awaited update on its therapy that uses a form of CRISPR called base editing to precisely fix a single genetic

Boehringer Ingelheim said it plans to keep up high levels of R&D spending, and could look at China-based companies for dealmaking, as key planks of

Plus, news about BrightGene and Apogee Therapeutics: 📊 More data on Novo Nordisk-United triple-G: The Danish drugmaker said its China-derived triple-G agonist led to mean

Spanish plasma medicine specialist Grifols is planning to sell a minority stake in its US business, via an IPO, to help pay down its debt.